Symbiotec Pharmalab IPO: Price Band, GMP, Dates, Lot Size & Everything You Need to Know

The Symbiotec Pharmalab IPO is a ₹1,757 crore mainboard issue comprising a ₹150 crore fresh issue and a ₹1,607 crore offer for sale. The Symbiotec Pharmalab IPO price band is ₹938-₹988 per share, with a lot size of 15 shares. The issue opens on August 24, 2026, and investors are tracking the Symbiotec Pharmalab IPO GMP today, allotment date, listing date and financial performance.

• Symbiotec Pharmalab IPO opens on August 24 and closes on August 27, 2026.

• The IPO has a price band of ₹938–₹988 with 15 shares in 1 lot.

• The total issue size of IPO is ₹1,757 crore, including ₹150 crore fresh issue and ₹1,607 crore OFS.

• Allotment is estimated for August 28, with listing on September 1, 2026 on NSE and BSE.

• MUFG Intime India is the registrar for this IPO.

The Symbiotec Pharmalab IPO issue size is ₹1,757 crore. This includes a ₹150 crore fresh issue and an offer for sale of about ₹1,607 crore by existing shareholders. The Symbiotec Pharmalab IPO price band has been fixed at ₹938–₹988 per share, while the lot size is 15 shares. At the upper price band, one lot requires a minimum investment of ₹14,820.

The IPO will open on August 24 and close on August 27. The basis of allotment is estimated for August 28, while the shares are expected to list on NSE and BSE on September 1. MUFG Intime India Pvt. Ltd. is the registrar. The book-running lead managers are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory & Securities.

The Symbiotec Pharmalab IPO GMP today is being closely watched as the issue attracts investor interest. As of August 23, grey-market trackers were reporting a GMP of around ₹409 per share. Against the upper price band of ₹988, this represents an indicative premium of about 41.40%.

However, GMP is an unofficial and unregulated market indicator. It can change before listing and should not be treated as a guaranteed listing price or return.

The Symbiotec Pharmalab IPO is scheduled to open on August 24, so subscription data is not available yet as of August 23. Once bidding begins, investors will be able to track overall and category-wise subscription figures for QIBs, NIIs and retail investors.

Symbiotec Pharmalab Limited is a pharmaceutical and biotech company based in India that was founded in 2002. The company's headquarters is located in Indore, Madhya Pradesh, India. It specializes in developing, manufacturing, and marketing APIs with a special emphasis on corticosteroids and steroidal hormones.

The company also provides contract development and manufacturing services to pharmaceutical, nutraceutical, and life-science businesses in domestic and international markets. Its portfolio includes more than 60 steroid and corticosteroid APIs, such as hydrocortisone, betamethasone, progesterone, estrogen, and testosterone-based products. Symbiotec Pharmalab combines research, backward-integrated manufacturing, and specialised production capabilities to support the development of pharmaceutical ingredients and injectable formulations.

Symbiotec Pharmalab's total income increased from ₹723.33 crore in FY24 to ₹872.26 crore in FY26. PAT, however, fell slightly in FY25 before recovering to ₹109.90 crore in FY26. EBITDA also increased to ₹231.97 crore in FY26.

The company will receive the proceeds from the ₹150 crore fresh issue, while proceeds from the ₹1,607 crore OFS will go to the selling shareholders.

Around ₹112.5 crore from the fresh issue is proposed to be used for prepayment or repayment of certain outstanding borrowings. The remaining amount is intended for general corporate purposes.

The Symbiotec Pharmalab IPO allotment date is decided at August 28, 2026. Refund initiation and credit of shares are expected on August 31, 2026, however, the listing date of this IPO is September 1, 2026, on NSE and BSE.

The Symbiotec Pharmalab IPO combines a specialised pharmaceutical API business with a ₹1,757 crore mainboard issue. Its ₹938–₹988 price band, 15-share lot size and recent improvement in revenue and profit make the issue one to track.

At the same time, investors should look beyond the Symbiotec Pharmalab IPO GMP today. The large OFS component, valuation, debt position, regulatory exposure and performance of its specialised API business are also important when evaluating the IPO.

Ans. The Symbiotec Pharmalab IPO opens on August 24, 2026, and will stay open for subscription until its end date, i.e August 27, 2026.

Ans. The Symbiotec Pharmalab IPO price band has been fixed at ₹938 to ₹988 per share. The upper price band of ₹988 is used to calculate the minimum investment required for one retail lot.

Ans. The Symbiotec Pharmalab IPO lot size is 15 shares. At the upper price band of ₹988, one lot requires a minimum investment of ₹14,820.

Ans. As of August 23, grey-market trackers were reporting GMP around ₹409 per share. However, GMP is unofficial, can change frequently and should not be considered a guaranteed indicator of the IPO's listing price or future returns.

Ans. The Symbiotec Pharmalab IPO allotment date is estimated for August 28, 2026, while the shares are expected to list on September 1, 2026, on NSE and BSE.